Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Ciro Mauro
Based on 1 article published since 2008
||||

Between 2008 and 2019, Ciro Mauro wrote the following article about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Guideline [SICI-GISE Position paper: Use of Absorb BVS in clinical practice]. 2016

Tarantini, Giuseppe / Saia, Francesco / Capranzano, Piera / Cortese, Bernardo / Mojoli, Marco / Boccuzzi, Giacomo / Cuculo, Andrea / Geraci, Salvatore / Mattesini, Alessio / Oreglia, Jacopo / Summaria, Francesco / Testa, Luca / Berti, Sergio / Esposito, Giovanni / La Manna, Alessio / Limbruno, Ugo / Marchese, Alfredo / Mauro, Ciro / Tarantino, Fabio / Salvi, Alessandro / Santoro, Gennaro / Varbella, Ferdinando / Violini, Roberto / Musumeci, Giuseppe. ·Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari, Policlinico Universitario, Padova. · Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna. · Dipartimento Cardiovascolare, Ospedale Ferrarotto, Università degli Studi, Catania. · Cardiologia Interventistica, A.O. Fatebenefratelli, Milano. · Cardiologia Interventistica, Azienda Sanitaria Locale Torino 2, Torino. · Dipartimento di Cardiologia, A.O. Ospedali Riuniti, Foggia. · Cardiologia Interventistica, Ospedale S. Giovanni di Dio, Agrigento. · Cardiologia Interventistica, Ospedale Moriggia Pelascini, Gravedona (CO). · Emodinamica, ASST Grande Ospedale Metropolitano Niguarda, Milano. · Dipartimento di Cardiologia, Policlinico Casilino, Roma. · Dipartimento di Cardiologia, IRCCS Policlinico S. Donato, S. Donato Milanese (MI). · U.O. Cardiologia Diagnostica ed Interventistica, Fondazione Toscana "Gabriele Monasterio", Ospedale del Cuore, Massa. · Dipartimento di Scienze Biomediche Avanzate, Università degli Studi "Federico II", Napoli. · U.O.C. Cardiologia, Azienda USL Toscana Sudest, Grosseto. · U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari. · Dipartimento Cardiovascolare, Ospedale Cardarelli, Napoli. · Laboratorio di Emodinamica, U.O. Cardiologia, Ospedale G.B. Morgagni-L. Pierantoni, Forlì. · Dipartimento Cardiovascolare, Ospedali Riuniti, Università degli Studi, Trieste. · Cardiologia Interventistica, AOU Careggi, Firenze. · Dipartimento di Cardiologia, Ospedale degli Infermi, Rivoli (TO). · Cardiologia Interventistica, Ospedale S. Camillo-Forlanini, Roma. · Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo. ·G Ital Cardiol (Rome) · Pubmed #27729667.

ABSTRACT: Drug-eluting stents (DES) are the current gold standard for percutaneous treatment of coronary artery disease. However, DES are associated with a non-negligible risk of long-term adverse events related to persistence of foreign material in the coronary artery wall. In addition, DES implantation causes permanent caging of the native vessel, thus impairing normal vasomotricity and the possibility of using non-invasive coronary imaging or preforming subsequent bypass surgery. On the contrary, coronary bioresorbable stents (BRS) may provide temporary mechanical support to coronary wall without compromising the subsequent recovery of normal vascular physiology, and have the potential to prevent late adverse events related to permanent elements. Several types of BRS have been introduced into clinical practice in Europe or are being tested. However, most of available clinical data relate to a single BRS, the Absorb bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA). Despite encouraging clinical results, no societal guidelines are available on the use of BRS in clinical practice.A panel of Italian expert cardiologists assembled under the auspices of the Italian Society of Interventional Cardiology (SICI-GISE) for comprehensive discussion and consensus development, with the aim to provide recommendations on the use of bioresorbable stents in terms of clinical indications, procedural aspects, post-percutaneous coronary angioplasty pharmacologic treatment and follow-up. Based on current evidence and BRS availability in Italian cath-labs, the panel decided unanimously to provide specific recommendations for the Absorb BVS device. These recommendations do not necessarily extend to other BRS, unless specified, although significant overlap may exist with Absorb BVS, particularly in terms of clinical rationale.